September 4, 2014 | The English High Court ruled in support of Israeli company Teva Pharmaceutical Industries in their case against Astra-Zeneca, a multi-national pharmaceutical and biologics company. According to the court, Astra-Zeneca will not be allowed to change their patent for the smart indication of Symbicort in order to facilitate Teva’s upcoming European launch of is asthma treatment DuoResp Spiromax, using Teva’s Spiromax technology.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments